Sanofi to Acquire Vicebio for USD 1.6 Billion
Sanofi has entered into a definitive agreement to acquire Vicebio Ltd., a biopharma company developing next-generation respiratory vaccines, in a deal worth up to USD 1.6 billion, including an upfront payment of USD 1.15 billion.
Dr. Giovanni Mariggi | 22/07/2025 | By Mrinmoy Dey | 107
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy